198 related articles for article (PubMed ID: 21897396)
21. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
[TBL] [Abstract][Full Text] [Related]
22. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy.
Chen KF; Yen CC; Lin JK; Chen WS; Yang SH; Jiang JK; Lan YT; Lin CC; Yu HC; Hsu HM; Lin WL; Teng HW
BMC Cancer; 2015 Apr; 15():301. PubMed ID: 25896895
[TBL] [Abstract][Full Text] [Related]
23. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
[TBL] [Abstract][Full Text] [Related]
24. Increased Expression of Holliday Junction-Recognizing Protein (HJURP) as an Independent Prognostic Biomarker in Advanced-Stage Serous Ovarian Carcinoma.
Li L; Li X; Meng Q; Khan AQ; Chen X
Med Sci Monit; 2018 May; 24():3050-3055. PubMed ID: 29743473
[TBL] [Abstract][Full Text] [Related]
25. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
[TBL] [Abstract][Full Text] [Related]
26. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.
Dong QZ; Wang Y; Dong XJ; Li ZX; Tang ZP; Cui QZ; Wang EH
Ann Surg Oncol; 2011 Mar; 18(3):857-65. PubMed ID: 20842459
[TBL] [Abstract][Full Text] [Related]
27. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis.
He H; Wu G; Li W; Cao Y; Liu Y
Diagn Mol Pathol; 2012 Sep; 21(3):143-9. PubMed ID: 22847158
[TBL] [Abstract][Full Text] [Related]
28. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
29. CIP2A expression predicts recurrences of tamoxifen-treated breast cancer.
Baldacchino S; Wastall LM; Saliba C; Hughes TA; Scerri C; Berwick A; Speirs V; Hanby AM; Grech G
Tumour Biol; 2017 Oct; 39(10):1010428317722064. PubMed ID: 29034804
[TBL] [Abstract][Full Text] [Related]
30. Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma.
Flørenes VA; Emilsen E; Dong HP; Førsund M; Holm R; Slipicevic A
Cancer Med; 2015 Jun; 4(6):903-13. PubMed ID: 25663244
[TBL] [Abstract][Full Text] [Related]
31. Fibronectin and Periostin as Prognostic Markers in Ovarian Cancer.
Kujawa KA; Zembala-Nożyńska E; Cortez AJ; Kujawa T; Kupryjańczyk J; Lisowska KM
Cells; 2020 Jan; 9(1):. PubMed ID: 31936272
[TBL] [Abstract][Full Text] [Related]
32. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.
De Stefano I; Zannoni GF; Prisco MG; Fagotti A; Tortorella L; Vizzielli G; Mencaglia L; Scambia G; Gallo D
Gynecol Oncol; 2011 Sep; 122(3):573-9. PubMed ID: 21665249
[TBL] [Abstract][Full Text] [Related]
33. CIP2A expression and localization in oral carcinoma and dysplasia.
Katz J; Jakymiw A; Ducksworth MK; Stewart CM; Bhattacharyya I; Cha S; Chan EK
Cancer Biol Ther; 2010 Oct; 10(7):694-9. PubMed ID: 21068540
[TBL] [Abstract][Full Text] [Related]
34. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
35. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients.
Moilanen J; Lassus H; Leminen A; Vaheri A; Bützow R; Carpén O
Gynecol Oncol; 2003 Aug; 90(2):273-81. PubMed ID: 12893187
[TBL] [Abstract][Full Text] [Related]
36. Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.
Khanna A; Thoms JAI; Stringer BW; Chung SA; Ensbey KS; Jue TR; Jahan Z; Subramanian S; Anande G; Shen H; Unnikrishnan A; McDonald KL; Day BW; Pimanda JE
Mol Cancer Res; 2020 May; 18(5):709-722. PubMed ID: 32079743
[TBL] [Abstract][Full Text] [Related]
37. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
Zhang J; Wang JC; Li YH; Wang RX; Fan XM
Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
[TBL] [Abstract][Full Text] [Related]
38. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
[TBL] [Abstract][Full Text] [Related]
39. Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer.
Chen W; Liang JL; Zhou K; Zeng QL; Ye JW; Huang MJ
Cell Commun Signal; 2020 Apr; 18(1):67. PubMed ID: 32321509
[TBL] [Abstract][Full Text] [Related]
40. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
